



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
C. A. M. van Riel,
✉ charlotte.vanriel@radboudumc.nl

RECEIVED 03 October 2024
ACCEPTED 07 October 2024
PUBLISHED 14 October 2024

CITATION
van Riel CAM, Michielsens CAJ, van Muijen ME,
van der Schoot LS, van den Reek JMPA and
de Jong EMGJ (2024) Corrigendum: Dose
reduction of biologics in patients with plaque
psoriasis: a review.
Front. Pharmacol. 15:1505626.
doi: 10.3389/fphar.2024.1505626

COPYRIGHT
© 2024 van Riel, Michielsens, van Muijen, van
der Schoot, van den Reek and de Jong. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or reproduction in
other forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review

C. A. M. van Riel^{1,2*}, C. A. J. Michielsens^{1,2}, M. E. van Muijen^{3,4},
L. S. van der Schoot^{1,2}, J. M. P. A. van den Reek^{1,2} and
E. M. G. J. de Jong^{1,2,5}

¹Radboud University Medical Centre, Nijmegen, Netherlands, ²Department of Dermatology, Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ³Maastricht University Medical Centre, Maastricht, Limburg, Netherlands, ⁴Department of Dermatology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands, ⁵Radboud University, Nijmegen, Gelderland, Netherlands

KEYWORDS

psoriasis, dose reduction, dose tapering, clinical practice, implementation, biologics, biologicals, (cost-)effectiveness

A Corrigendum on

Dose reduction of biologics in patients with plaque psoriasis: a review

by van Riel CAM, Michielsens CAJ, van Muijen ME, van der Schoot LS, van den Reek JMPA and de Jong EMGJ (2024). *Front. Pharmacol.* 15:1369805. doi: 10.3389/fphar.2024.1369805

In the published article, there was an error. The symbol ' \leq ', in the phrase "[...] biologic use for ≤ 6 months [...]" is incorrect. This should be the symbol ' \geq '.

A correction has been made to the **Discussion**, Paragraph 1. This sentence previously stated:

"Considering the studies on DR strategies, the eligibility criteria for DR mainly included biologic use for ≤ 6 months, a stable low disease activity from ≥ 6 months to ≥ 1 year, determined by an absolute or relative PASI (PASI $\leq 3/\leq 5$ /PASI 75–100) and/or DLQI $\leq 3/\leq 5$, or BSA $\leq 1/\leq 2$, or PGA $\leq 1/0-2$ during a period ranging from 12 weeks to ≥ 1 year (Atalay et al., 2021; Aubert et al., 2022; Atalay et al., 2022b; van der Schoot et al., 2022b; Di Altobrando et al., 2022; van Muijen et al., 2022; Herranz-Pinto et al., 2023)."

The corrected sentence appears below:

"Considering the studies on DR strategies, the eligibility criteria for DR mainly included biologic use for ≥ 6 months, a stable low disease activity from ≥ 6 months to ≥ 1 year, determined by an absolute or relative PASI (PASI $\leq 3/\leq 5$ /PASI 75–100) and/or DLQI $\leq 3/\leq 5$, or BSA $\leq 1/\leq 2$, or PGA $\leq 1/0-2$ during a period ranging from 12 weeks to ≥ 1 year (Atalay et al., 2021; Aubert et al., 2022; Atalay et al., 2022b; van der Schoot et al., 2022b; Di Altobrando et al., 2022; van Muijen et al., 2022; Herranz-Pinto et al., 2023)."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.